Targeting complement in IgA nephropathy.

Authors:
Caravaca-Fontán F; Gutiérrez E; Sevillano ÁM; Praga M.

Journal:
Clin Kidney J

Publication Year: 2023

DOI:
10.1093/ckj/sfad198

PMCID:
PMC10695513

PMID:
38053977

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Clin Kidney J

Abbreviation: Clin Kidney J

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Urology & Nephrology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Actioning the findings of hard endpoint clinical trials as they emerge in the realm of chronic kidn…
Strippoli GFM; Green SC. (2024) - Transparency Score: 2/6
Anticoagulation in patients with end-stage kidney disease and atrial fibrillation: a national popul…
Kim DG; Kim SH; Park SY and 5 more (2024) - Transparency Score: 2/6
Characterization of glomerular basement membrane components within pediatric glomerular diseases.
Chen D; Zhou X; Gan C and 11 more (2024) - Transparency Score: 3/6
Dapagliflozin in chronic kidney disease: cost-effectiveness beyond the DAPA-CKD trial.
McEwan P; Davis JA; Gabb PD and 7 more (2024) - Transparency Score: 3/6
Elimination and penetration of amikacin into urine in patients with decreased glomerular filtration…
Hartinger JM; Dvořáčková E; Krátký V and 11 more (2024) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"CONFLICT OF INTEREST STATEMENT None declared."

Evidence found in paper:

"FUNDING This paper was published as part of a supplement funded by an educational grant from Otsuka America Pharmaceutical, Inc."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025